Mar 24, 2021 / 12:15PM GMT
Sarah Cue Kiely - ProQR Therapeutics N.V. - VP of IR & Corporate Communications
Thank you, operator, and good day, everyone. I am Sarah Kiely, Vice President of Investor Relations and Corporate Communications at ProQR. We are very pleased to share with you the findings for our Phase I/II Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa as well as the next steps for the program.
Briefly, some logistics. The webcast can be accessed under the Investors Events section of our website at www.proqr.com and will be available for replay later today. The slides for the webcast can be downloaded from the webcast player or directly from our website.
We will first go through our presentation and then open the call for questions. In order to include your question on today's call, we request that you call into the telephone numbers provided in today's press release.
During the call today, we will make forward-looking statements. There are risks and uncertainties associated with an investment in
ProQR Therapeutics NV to Discuss the Results of Phase 1/2 Stellar trial of QR-421a in Adults with Usher Syndrome and nSRP Transcript
Mar 24, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers